Dual therapy based on raltegravir and boosted protease inhibitors - the experience of Polish centers
| Autor: | Miłosz Parczewski, Ewa Siwak, Łukasz Pulik, Anna Kalinowska, Kamila Wójcik, Jacek Gąsiorowski, Piotr Pulik, Monika Bociąga-Jasik, Elżbieta Jabłonowska, Elżbieta Mularska |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
medicine.medical_specialty
animal structures protease inhibitors Integrase inhibitor 03 medical and health sciences 0302 clinical medicine Pharmacotherapy Clinical Research Internal medicine medicine 030212 general & internal medicine Adverse effect 030505 public health business.industry HIV dual therapy General Medicine medicine.disease Raltegravir Discontinuation Regimen Ritonavir raltegravir 0305 other medical science business medicine.drug Kidney disease |
| Zdroj: | Archives of Medical Science : AMS |
| Popis: | Introduction: The aim of the study was to present the experience of Polish centers regarding dual therapy based on the integrase inhibitor raltegravir (RAL) and ritonavir-boosted protease inhibitors (PI/r) for treating treatment-naïve and -experienced HIV-infected patients. Material and methods: The paper concerns a retrospective multicenter study. The medical databases of six main Polish HIV centers from January 2009 to December 2014 were analyzed for the use of combined antiretroviral treatment consisting of RAL + PI/r. This study included 126 HIV-infected patients receiving RAL + PI/r therapy, of whom 17 patients were treatment-naive and 109 patients were treatment-experienced. Results: In treatment-experienced patients, the most common reasons for the introduction of a RAL + PI/r regimen were virologic failure and impaired renal function (45 of 109 patients). In the treatment-naïve group kidney disease was the cause of the RAL + PI/r regimen in 3 of 17 participants. In treatment-experienced patients, 80% of individuals still were on RAL + PI/r treatment after 12 months, 65% after 24 months and 53% of subjects after 60 months. In both groups, the simplification of the antiretroviral regimen was the most common reason for discontinuation of RAL + PI/r based therapy. Conclusions: In antiretroviral-experienced patients the dual therapy based on RAL + PI/s is safe and effective. In antiretroviral-naïve patients the RAL + PI/r regimen is rarely used in Poland. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|